Loading company…
Riskpilot
← Back to search
Sign in
Get full access
Pharma Consult ApS
APS
Active
CVR 43801708
Jespervej 58
Engineering activities and related technical consultancy · NACE 7112
Est. 2023
1 employees
Watchlist
Share
Overview
Financials
People & ownership
Related companies
Revenue 2025
DKK 1,1M
-17% vs 2024
EBITDA margin
40.3%
-24% vs 2024
Equity ratio
67.9%
Financial strength
Net profit 2025
DKK 343K
-26% vs 2024
EBITDA — year on year
DKK millions
1M
1M
1M
0M
0M
1M
2023
1M
0%
2024
0M
-100%
2025
Key figures
Annual report 2025
Revenue
DKK 1,1M
-17%
EBITDA
DKK 463K
-24%
Net profit
DKK 343K
-26%
Total assets
DKK 2M
+41%
Equity
DKK 1,4M
+34%
Employees
1
—
Company information
Legal name
Pharma Consult ApS
CVR number
43801708
Legal form
Anpartsselskab
NACE code
7112 · Engineering activities and related technical consultancy
Founded
24. januar 2023
Share capital
DKK 40.000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Virksomheden tegnes af en direktør
Company purpose
Virksomhedens formål er anden teknisk rådgivning.
Contact
Address
Jespervej 58
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
Visit risika.com
Explore
Companies in Engineering activities and related technical consultancy
Companies in Hillerød
All Denmark companies
Revenue
DKK millions
0M
0M
1M
1M
1M
1M
2023
1M
2024
1M
2025
EBITDA
DKK millions
0M
0M
1M
1M
1M
1M
2023
1M
2024
0M
2025
Income statement
DKK thousands
Item
2023
2024
2025
Revenue
1.454
1.391
1.148
Staff expenses
-790
-783
-686
EBITDA
664
608
463
Depreciation & amort.
-0
-0
-0
EBIT
664
608
463
Net financials
-5
-13
-14
Profit before tax
659
595
449
Tax
149
133
106
Net profit
510
462
343
Balance sheet
DKK thousands
Item
2023
2024
2025
Total assets
885
1.415
1.997
Equity
550
1.012
1.356
Long-term debt
0
0
0
Short-term debt
335
403
641
Total debt
335
403
641
Financial ratios
5-year trend
EBITDA margin
40.3%
This company
15.8%
Market median
+155% vs market
2023
2025
Equity ratio
67.9%
This company
38.2%
Market median
+78% vs market
2023
2025
Return on equity
25.3%
This company
18.4%
Market median
+38% vs market
2023
2025
Net profit margin
29.9%
This company
8.1%
Market median
+269% vs market
2023
2025
Asset turnover
0.58×
This company
1.12×
Market median
-48% vs market
2023
2025
Debt / equity
0.47×
This company
0.62×
Market median
+24% vs market
2023
2025
Annual reports & filings
Annual report 2025
Filed via CVR / Virk · Period 2025-01-01 – 2025-12-31
View
PDF
Annual report 2024
Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
View
PDF
Annual report 2023
Filed via CVR / Virk · Period 2023-01-24 – 2023-12-31
View
PDF
Management
Actively employed in the business
No data on file.
Board of directors
Non-executive oversight
No data on file.
Shareholders
As of last annual report
Shareholder
Type
Ownership
Votes
Since
Shahin Jolaini
Individual
100%
100%
2023
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive.
Learn more
.
Company hierarchy
No registered parent or subsidiaries
Board network connections
Board members of Pharma Consult ApS also hold positions in
0
other companies.
Person
Role here
Other companies